Results 161 to 170 of about 722,373 (248)

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest   +3 more
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou   +5 more
wiley   +1 more source

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park   +5 more
wiley   +1 more source

Ablation for Persistent Atrial Fibrillation

open access: yesJACC: Clinical Electrophysiology, 2015
Bradley P. Knight, Albert C. Lin
openaire   +1 more source

SGLT2 Inhibitors and Cardiovascular Outcomes in Patients With Fabry Disease: Observations From a Federated Research Network

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background and Aim Fabry disease (FD) is frequently complicated by renal impairment and cardiovascular events; however, evidence on sodium–glucose cotransporter‐2 inhibitors (SGLT2i) in this population is scarce. Accordingly, we assessed the association between SGLT2i exposure and cardiovascular outcomes in adults with FD. Methods We conducted
Leandra Serio   +8 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto   +12 more
wiley   +1 more source

Bioimpedance and Symptom Guided Fluid Management in Hemodialysis: A Multicenter Pre–Post Implementation Study

open access: yesHemodialysis International, EarlyView.
ABSTRACT Background Optimizing volume status is central to hemodialysis care and may influence patient‐reported outcome measures as recovery time. We evaluated the implementation of a structured decision aid (Recova) integrating symptom assessment with bioimpedance spectroscopy in routine hemodialysis practice.
Maaike Nielen   +7 more
wiley   +1 more source

A multicentre evaluation of cardiovascular risk prediction tools in people living with HIV across England (ECARTH study)

open access: yesHIV Medicine, EarlyView.
Abstract Introduction It remains unclear which cardiovascular disease (CVD) risk scores are optimized for people living with treated HIV with high rates of viral suppression. We evaluated the performance of commonly used CVD risk scores in a population of primarily well‐treated HIV patients in England.
Ming Jie Lee   +23 more
wiley   +1 more source

Trajectory of macrotroponin in a community cohort

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background Cardiac troponin I (cTnI) is a biomarker for myocardial injury. However, macrotroponin, a complex of cTnI and endogenous cardiac troponin autoantibodies, may artefactually elevate cTnI levels with potential to mislead clinicians, leading to inappropriate investigation and management.
Duncan J. Campbell   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy